SG11201703307WA - Therapy for inhibition of single-stranded rna virus replication - Google Patents

Therapy for inhibition of single-stranded rna virus replication

Info

Publication number
SG11201703307WA
SG11201703307WA SG11201703307WA SG11201703307WA SG11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA
Authority
SG
Singapore
Prior art keywords
inhibition
therapy
stranded rna
rna virus
virus replication
Prior art date
Application number
SG11201703307WA
Inventor
Reza Fathi
Dror Ben-Asher
Guy Goldberg
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of SG11201703307WA publication Critical patent/SG11201703307WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201703307WA 2014-10-24 2015-10-23 Therapy for inhibition of single-stranded rna virus replication SG11201703307WA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462068487P 2014-10-24 2014-10-24
US201462068469P 2014-10-24 2014-10-24
US201462068477P 2014-10-24 2014-10-24
US201462068492P 2014-10-24 2014-10-24
US201462068465P 2014-10-24 2014-10-24
US201562188030P 2015-07-02 2015-07-02
PCT/IB2015/002173 WO2016063134A1 (en) 2014-10-24 2015-10-23 Therapy for inhibition of single-stranded rna virus replication

Publications (1)

Publication Number Publication Date
SG11201703307WA true SG11201703307WA (en) 2017-05-30

Family

ID=55760346

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703307WA SG11201703307WA (en) 2014-10-24 2015-10-23 Therapy for inhibition of single-stranded rna virus replication

Country Status (12)

Country Link
US (5) US9974800B2 (en)
EP (2) EP4134076A1 (en)
JP (1) JP6625631B2 (en)
KR (1) KR20170070234A (en)
CN (2) CN112999222B (en)
AU (2) AU2015334590B2 (en)
BR (1) BR112017008220A2 (en)
CA (1) CA2965258C (en)
IL (1) IL251847A0 (en)
MX (1) MX2017005350A (en)
SG (1) SG11201703307WA (en)
WO (1) WO2016063134A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
AU2016336133B2 (en) * 2015-10-06 2021-02-25 Redhill Biopharma Ltd. Combination therapies for treating cancer
CN108853106B (en) * 2017-05-09 2021-02-02 中国食品药品检定研究院 Use of imine phenazine compound as rabies virus inhibitor
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. Enantiomerically pure adamantane derivatives for the treatment of filovirus infection
DE102018217334A1 (en) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents
WO2020185637A1 (en) * 2019-03-08 2020-09-17 The Texas A&M University System Rose rosette virus infectious clones and uses thereof
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
MX2022011173A (en) * 2020-03-10 2022-10-18 Redhill Biopharma Ltd Treatment of coronavirus infection.
EP3932409A1 (en) * 2020-06-29 2022-01-05 Consejo Superior de Investigaciones Científicas (CSIC) Compounds for the treatment and prevention of viral infections caused by coronaviruses
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
SK662001A3 (en) 1998-07-15 2001-10-08 Hassan Jomaa Phosphorous organic compounds and their use
US7204980B2 (en) * 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
CN101248041B (en) * 2005-06-17 2013-11-20 艾宝奇生物工艺有限公司 Sphingosine kinase inhibitors
GB0803707D0 (en) * 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
KR101420094B1 (en) * 2010-10-27 2014-07-17 (주)바이오니아 Automatic realtime PCR system for the various analysis of biological sample, method for Automatic nucleic acid purification and realtime quantification of gene amplification, method for automatic viable cell count of pathogenic bacteria using realtime quantitative PCR, method for automatically getting antigene density using quantitative immunity PCR
US9687477B2 (en) * 2011-06-01 2017-06-27 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand RNA virus infections
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
AU2016336133B2 (en) * 2015-10-06 2021-02-25 Redhill Biopharma Ltd. Combination therapies for treating cancer

Also Published As

Publication number Publication date
JP6625631B2 (en) 2019-12-25
CA2965258C (en) 2023-09-19
US9974800B2 (en) 2018-05-22
KR20170070234A (en) 2017-06-21
CN112999222B (en) 2024-05-28
CN107106525B (en) 2021-03-19
BR112017008220A2 (en) 2018-01-09
CN112999222A (en) 2021-06-22
EP3209290A1 (en) 2017-08-30
AU2019271958A1 (en) 2019-12-19
IL251847A0 (en) 2017-06-29
US20180318328A1 (en) 2018-11-08
MX2017005350A (en) 2017-08-15
AU2015334590B2 (en) 2019-08-29
EP3209290A4 (en) 2018-11-14
WO2016063134A1 (en) 2016-04-28
US20240108643A1 (en) 2024-04-04
AU2019271958B2 (en) 2020-03-05
US11786541B2 (en) 2023-10-17
CA2965258A1 (en) 2016-04-28
JP2017531673A (en) 2017-10-26
EP4134076A1 (en) 2023-02-15
US10543222B2 (en) 2020-01-28
US20210369754A1 (en) 2021-12-02
AU2015334590A1 (en) 2017-05-18
US11090325B2 (en) 2021-08-17
US20200155585A1 (en) 2020-05-21
US20160113954A1 (en) 2016-04-28
CN107106525A (en) 2017-08-29

Similar Documents

Publication Publication Date Title
IL251847A0 (en) Therapy for inhibition of single-stranded rna virus replication
HK1225968A1 (en) Combination therapy for treatment of hbv infections
IL253945A0 (en) Kdm1a inhibitors for the treatment of disease
IL247973A0 (en) Methods for purification of messenger rna
SG11201707663SA (en) Lyophilization of rna
PT3212233T (en) Combination therapy for treatment of disease
SG11201701723XA (en) Methods of treating liver disease
GB201701673D0 (en) Methods of well treatment
PT3286166T (en) Inhibitors of human immunodeficiency virus replication
IL247364A0 (en) Inhibitors of c5a for the treatment of viral pneumonia
HK1225617A1 (en) 4’-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
HK1251166A1 (en) Targeted treatment of leiomyosarcoma
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
HK1232220A1 (en) Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases 5-
HUE049600T2 (en) Gls1 inhibitors for treating diseases
HK1258994A1 (en) Methods for treatment of diseases
HK1252245A1 (en) Nucleotides for the treatment of cancer
GB201416832D0 (en) Methods of treatment
PT3107913T (en) Inhibitors of human immunodeficiency virus replication
PT3105236T (en) Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
GB201412010D0 (en) Treatment of hypertransaminasemia
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
GB201403369D0 (en) RNA Virus induced gene expression
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors